PharmaShots Magazine - June 2024 Edition

Share this

PharmaShots Magazine - June 2024 Edition

May had been a busy month for PharmaShots with an unceasing influx of life science updates.  

In our most-read Top 20 section, we published reports on Diagnostic Companies and Medical Device Companies

Like every month, PharmaShots published reports on Key Biosimilars Events, FDA approvals, and EMA approvals along with the New Drug Designation Report. In the Disease of the Month report, we explored Sjögren’s syndrome. The May Edition of Know Your Investor featured Alexandria Venture Investment

As an annual custom, we published an analysis of the Growth of Biopharma Companies in the Last 20 years (2004-2023) 

A theme as diverse as MedTech can be hard to encompass in a single digest/magazine. For the subsequent two months, PharmaShots Magazine will be exploring MedTech as a field.  

To spice up the theme, PharmaShots decided to navigate the theme based on the US FDA’s classification of Medical Devices. This Month, we are focusing on Class I and Class II medical devices, and for the next month, our focus will be solely on Class III medical devices. 

Want to advertise in PharmaShots Magazine for FREE? Email us at connect@pharmashots.com

Aditya Singh

Aditya brings a wealth of knowledge and expertise to Pharmashots, having spent his career at top-tier knowledge research and consulting firms. He has a proven track record of success in collaborating with a diverse range of clients, including leading global pharmaceutical and biotechnology companies. As Editor-in-Chief of Pharmashots, Aditya leverages his deep understanding of the life sciences landscape to curate insightful and impactful content, ensuring readers stay informed about the latest advancements in pharmaceuticals, biotechnology, MedTech, digital health, and the broader life sciences industry. Connect with Aditya on LinkedIn to stay up-to-date on the latest industry trends and insights.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions